Trial Profile
A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Emvododstat (Primary)
- Indications Cancer; Neurofibromatoses
- Focus Therapeutic Use
- Sponsors PTC Therapeutics
- 24 Aug 2018 Status changed from suspended to discontinued.
- 06 Apr 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned End Date changed from 1 May 2011 to 1 May 2012 as reported by ClinicalTrials.gov.